No serious side effects were observed in the Phase I trial
News
Regeneron, AZ partner on development of novel obesity drugs
Collaboration will focus on developing small molecule medicines targeting GPR75
NICE publishes new draft guideline covering rehabilitation after traumatic injury
A traumatic injury includes any injury that requires admission to hospital at the time of injury, according to NICE
EU backs approval of Moderna’s COVID-19 vaccine in 12-17 year-olds
Study in adolescents met it primary endpoint, successfully bridging immune responses to those observed in an efficacy study in adults
Organon and ObsEva to collaborate on preterm labour treatment
Organon will license the global development, manufacturing and commercial rights to investigational treatment ebopiprant
BioNTech to develop a mRNA-based malaria vaccine
Clinical trial for first vaccine candidate is planned for the end of 2022
Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients
Combo therapy includes carflizomib administered alongside lenalidomide, dexamethasone and cyclophosphamide
Researchers find extending the time between Pfizer doses boosts antibodies
Eight weeks between doses is the ‘sweet spot’ according to researchers
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
NICE, PHE publish new antimicrobial prescribing guideline on C. difficile infection
New recommendations outlined include advice for managing C. difficile infection in both community and hospital settings
New plans to improve patient access to mental health services unveiled in England
NHS England has set out new plans to introduce five new waiting time guarantees for mental health services
Seres’ ulcerative colitis candidate misses primary endpoint in mid-stage study
Microbiome-based therapeutic failed to improve clinical remission rates among mild-to-moderate ulcerative colitis patients
AZ says its COVID-19 vaccine protects against severe disease caused by variants
Real-world data shows jab is effective after one dose against hospitalisation/death caused by Beta and Delta variants
Albireo’s Bylvay approved in EU and US for rare paediatric liver disease
PFIC is a rare and progressive liver disease affecting young children which can lead to cirrhosis and liver failure
Nanopharm and Leyden Labs link up in nasal spray partnership
Partnership will aim to develop nasal spray drug products for prophylactic use against respiratory viruses
